Navigation Links
Ohr Pharmaceutical Achieves 50% Enrollment Milestone in Squalamine Eye Drop Phase II Clinical Trial
Date:7/10/2013

NEW YORK, July 10, 2013 /PRNewswire/ -- Ohr Pharmaceutical, Inc. (NasdaqCM:OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, today announced that it has enrolled the first 60 patients in the Company's ongoing OHR-002 Phase II clinical trial evaluating Squalamine Eye Drops for the treatment of the wet form of age-related macular degeneration ("wet-AMD"). The study is a randomized, double blind, placebo controlled study enrolling patients at more than twenty clinical sites in the U.S.

"We are excited to have reached the halfway point in the enrollment of our Squalamine Eye Drop study," said Dr. Irach B. Taraporewala, CEO of Ohr. "This milestone sets the stage for the planned interim analysis once the 60 patients complete the nine month treatment protocol, and we expect the data to be available in the second quarter of 2014."

"I am pleased with the continued progress in the trial to evaluate Squalamine Eye Drops for exudative AMD," commented Dr. Jason Slakter, retinal disease specialist at Vitreous-Retina-Macula Consultants of NY, and member of Ohr's scientific advisory board. "The Company's eye drop for treating wet-AMD would potentially offer patients a convenient, self-administered, treatment alternative or adjunct to currently used intravitreal injections directly into the eye. This could be a significant advancement in the future treatment of wet-AMD."

Study OHR-002 is a randomized, double blind, placebo controlled Phase II study to evaluate the efficacy and safety of Squalamine Eye Drops for the treatment of wet-AMD. The study will enroll 120 treatment naive wet-AMD patients at more than twenty clinical sites in the U.S., who will be treated with Squalamine Eye Drops or placebo eye drops twice daily for a nine month period. The primary and secondary endpoints include visual acuity parameters, need for rescue intravitreal inj
'/>"/>

SOURCE Ohr Pharmaceutical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Internal and External Communications Excellence for the Pharmaceutical Industry: Increasing Organizational Effectiveness
3. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
4. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
5. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
6. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
7. The respective roles of the public and private sectors in pharmaceutical innovation
8. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
9. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
10. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
11. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... building materials using light, developed by researchers at the ... are often considered the realm of science fiction, such ... cloaked starships won,t be a reality for quite some ... materials with building blocks a few billionths of a ... that light flies through them, and works on large ...
(Date:7/28/2014)... , July 28, 2014 Sapphire ... technologies, today announced the appointment of biotechnology veteran ... the board of directors. Levine replaces Cynthia ,CJ, Warner, ... She will remain chairman of the company,s board of ... Sapphire Energy,s mission to deliver commercial scale algae-based fuels ...
(Date:7/28/2014)... The Workgroup for Electronic Data Interchange ... of health IT to create efficiencies in healthcare information ... Workgroup has developed an issue brief titled, “What ... The HPID Workgroup, a part of WEDI’s Strategic National ... Medicare and Medicaid Services (CMS) to identify common misuse ...
(Date:7/28/2014)... “2014 Deep Research Report ... a professional and in-depth research report on ... introduces Lubricant basic information, including Lubricant definition, ... industry overview. This research covers the international ... well as global industry analysis covering macroeconomic ...
Breaking Biology Technology:Building 'invisible' materials with light 2Sapphire Energy Announces New CEO James Levine 2Sapphire Energy Announces New CEO James Levine 3WEDI’s HPID Workgroup Announces Release of Issue Brief: “What is the Difference Between a Health Plan and Payer?” 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 2Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 3Lubricant Market & Adhesion Promoter Industry (Globa, China) Analysis Now Available at DeepResearchReports.com 4
... of Integrated Global Services, CAMBRIDGE, Mass., April ... under a new name, Abt Bio-Pharma Solutions, Inc., ... company will continue to,provide custom strategic, research and ... diagnostics industries,utilizing a team approach that blends decades ...
... 1, 2008 Cardium Therapeutics,(Amex: CXM ... announced today that,InnerCool has entered into a ... a leading distributor of cardiology,medical products. Under ... have,exclusive marketing, sales and distribution rights in ...
... N.J., April 1, 2008 Derma Sciences,Inc (OTC Bulletin ... that sales for 2007 were $34.1 million, an increase ... Gross margins held steady at 34,percent, but due primarily ... the,pipeline, and expanding the Company,s marketing and sales staffs, ...
Cached Biology Technology:Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc. 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 2Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 3Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 4Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 5Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 6Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 7Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 8Cardium's InnerCool Therapies Unit Announces European Commercialization Agreement for Portfolio of Temperature Modulation Systems 9Derma Sciences Reports Fourth Quarter Year-End Results for 2007 2Derma Sciences Reports Fourth Quarter Year-End Results for 2007 3Derma Sciences Reports Fourth Quarter Year-End Results for 2007 4Derma Sciences Reports Fourth Quarter Year-End Results for 2007 5
(Date:7/28/2014)... About 100 drugs already approved by the U.S. Food ... prevent the growth of certain bacterial pathogens inside human ... Mediterranean spotted fever. The findings, published in mBio ... for Microbiology, demonstrate a new way of identifying non-antibiotic ... , A handful of drugs on the list ...
(Date:7/28/2014)... showing signs of damage from the Deepwater Horizon oil spill ... Gulf of Mexico. The discovery was made by a team ... University. A paper describing this work and additional impacts of ... be published during the last week of July 2014 in ... the National Academy of Sciences . , "The footprint of ...
(Date:7/28/2014)... the South Pole in 1911, but new research shows ... , Using data from 16 ice cores collected from ... South Pole, a group led by Joe McConnell of ... the most accurate and precise reconstruction to date of ... described in an article published today in the online ...
Breaking Biology News(10 mins):New route to identify drugs that can fight bacterial infections 2Impact of Deepwater Horizon oil spill on coral is deeper and broader than predicted 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... ,This multidisciplinary conference on "Fibrous Protein Nanocomposites for Tailored ... the art in the design, synthesis and characterization of ... applications. The conference will be held in the ... situated at the crossroads of the Mediterranean Sea, exposed ...
... Alejandro Heuck at the University of Massachusetts Amherst recently ... of Health to map the molecular structure of a ... in mammalian cell walls. Once a channel ... plague (Yersinia pestis), dysentery (Shigella), food poisoning (Salmonella) and ...
... - Scientists could take greater strides toward crop improvement ... to understand the mechanisms that allow plants to adapt ... say. In a perspective for the journal ... genetics, and Ivan Baxter, a research computational biologist for ...
Cached Biology News:Fibrous Protein Nanocomposites Conference 2Fibrous Protein Nanocomposites Conference 3UMass Amherst biochemists developing tools to stop plague and other bacterial threats 2UMass Amherst biochemists developing tools to stop plague and other bacterial threats 3Adoption of advanced techniques could propel crop improvement 2
22 x 50 mm; No. 1 thickness range: 0.13 to 0.17 mm, suitable for work in histology, cytology, urinalysis and microbiology, precleaned, store at room temperature ...
... 100%,S-Adenosyl Methionine 2.5%,Adenosine ... <0.1%,Cystathionine ... <0.1%,Glutathione ... Assay Range: 0.1 ug/ml to 1 mg/ml,(0.26 M to 2.6 mM) ...
Panomer 9 oligodeoxynucleotides are random primers that are labeled at the 5' end with our proprietary QSY 7 dye and they are useful for assessing microarray spot morphology, hybridization potential ...
Topoisomerase I, isolated from wheat germ, is an enzyme capable of removing negative supercoils from covalently closed circular DNA (1)....
Biology Products: